About PreludeDx
PreludeDx is a company based in Laguna Hills (United States) founded in 2009. PreludeDx has raised $51.65 million across 7 funding rounds from investors including GenesisCare and Evidity Health Capital. The company has 33 employees as of December 31, 2021. PreludeDx offers products and services including DCISionRT. PreludeDx operates in a competitive market with competitors including Raysearch laboratories, Miltel, OncoStem, Inbiomotion and POC Medical Systems, among others.
- Headquarter Laguna Hills, United States
- Employees 33 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Prelude Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$51.65 M (USD)
in 7 rounds
-
Latest Funding Round
$5 M (USD), Series B
Oct 30, 2025
-
Investors
GenesisCare
& 1 more
-
Employee Count
33
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PreludeDx
PreludeDx offers a comprehensive portfolio of products and services, including DCISionRT.
Predicts radiation benefit and recurrence risk for DCIS patients.
People of PreludeDx
Unlock access to complete
Unlock access to complete
Funding Insights of PreludeDx
PreludeDx has successfully raised a total of $51.65M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $5 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PreludeDx
PreludeDx has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include GenesisCare and Evidity Health Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Late-stage venture capital and growth equity investments are managed by Evidity Health Capital.
|
Locked | Locked | Locked | |
|
A chain of multi-speciality clinics is operated in Australia.
|
Locked | Locked | Locked |
Investor details for PreludeDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PreludeDx
Investment portfolio details for PreludeDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PreludeDx
Detailed financials for PreludeDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Preludedx Comparisons
Peer comparison for PreludeDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PreludeDx
PreludeDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Raysearch laboratories, Miltel, OncoStem, Inbiomotion and POC Medical Systems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cloud-based radiation therapy software is developed for oncology professionals.
|
|
| Locked | Locked | Locked |
Telomere tests for aging detection and cellular senescence are provided.
|
|
| Locked | Locked | Locked |
Prognostic tests for cancer detection and recurrence risk are developed.
|
|
| Locked | Locked | Locked |
Biomarkers for predicting bone metastasis in cancer patients are developed.
|
|
| Locked | Locked | Locked |
Develops rapid tools for breast cancer detection and disease screening worldwide.
|
Detailed competitors of PreludeDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Preludedx
Complete news archive for PreludeDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PreludeDx
PreludeDx was founded in 2009 and raised its 1st funding round 7 years after it was founded.
PreludeDx is headquartered in Laguna Hills, United States. It is registered at Laguna Hills, California, United States.
Daniel Forche is the current CEO of PreludeDx.
PreludeDx is a funded company, having raised a total of $51.65M across 7 funding rounds to date.
As of Dec 31, 2021, the latest employee count at PreludeDx is 33.
Founded in 2009 and headquartered in Laguna Hills, United States, PreludeDx operates in the medical diagnostics sector. Risk assessment tests for early-stage breast cancer are developed and offered, with the DCISionRT product focused on ductal carcinoma in situ (DCIS) patients. Disease-associated biomarkers and proprietary algorithms are utilized to classify patients into high- and low-risk groups, while treatment predictions for cancer patients are also generated through the system.
PreludeDx's top competitors include Raysearch laboratories, OncoStem and Biotheranostics.
PreludeDx offers DCISionRT.
PreludeDx has 2 investors. Key investors include GenesisCare, and Evidity Health Capital.